<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164435</url>
  </required_header>
  <id_info>
    <org_study_id>CI-12-044-AU-HT</org_study_id>
    <nct_id>NCT02164435</nct_id>
  </id_info>
  <brief_title>Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation</brief_title>
  <acronym>RDN</acronym>
  <official_title>Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single centre clinical investigation looking at short (6 months) and
      long term (24 months) changes in cardiac function and renal function in patients with
      drug-resistant hypertension post renal sympathetic denervation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Function (evaluated by MRI)</measure>
    <time_frame>Baseline and 6 Months</time_frame>
    <description>MRI Indices of Cardiac Function
Myocardial mass and myocardial fibrosis
Atrial and ventricular ejection function
Myocardial perfusion
Arterial distensibility</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Function (evaluated by MRI)</measure>
    <time_frame>Baseline, 6 Months and 24 Months</time_frame>
    <description>MRI Indices of Renal Function:
Renal blood flow
Renal perfusion
Urinary protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Baseline and 24 Months</time_frame>
    <description>MRI Indices of Cardiac Function
Myocardial mass and myocardial fibrosis
Atrial and ventricular ejection function
Myocardial perfusion
Arterial distensibility</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.</intervention_name>
    <arm_group_label>Renal Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be able and willing to comply with the required follow-up schedule

          -  Therapeutic Goods Association approved indications for EnligHTN™ Renal Denervation
             System

          -  Subject is ≥ 18 years of age at time of consent Subject has office SBP ≥ 160 mmHg
             (except for subjects with Diabetes Mellitus who must demonstrate an office SBP of ≥
             150 mm Hg) within 14 days of the procedure ◦Subject is taking ≥ 3 antihypertensive
             medications concurrently at maximum tolerated dose (this must include one diuretic) or
             subject has a documented intolerance to at least 2 out of the 4 major classes of
             anti-hypertensives (ACE/ARB, CCB, Diuretics, Beta Blockers and is unable to take 3
             antihypertensive drugs.

        Exclusion Criteria:

          -  Standard CMR exclusions;

               -  implanted cardiac device

               -  intracranial metallic implants

               -  claustrophobia -Gadolinium-specific: estimated GFR &lt;60 mls/min (usual clinical
                  cut-off is &lt;30 mls/min).

          -  Adenosine-specific:

               -  asthma / reactive airways disease

               -  &gt;first degree atrioventricular block

               -  concomitant use of dipyridamole or theophylline consumption of caffeine within 48
                  hours of proposed investigation

               -  EnligHTN™ Renal Denervation System exclusion criteria:

        Subject has an identified cause of secondary hypertension

          -  Subject has an estimated GFR &lt;45 mL/min per 1.73 m2 using the MDRD formula

          -  Subject has undergone prior renal angioplasty, indwelling renal stents, and/or aortic
             stent grafts

          -  Subject has haemodynamically significant valvular heart disease

          -  Subject has a life expectancy less than 12 months, as determined by the PI

          -  Subject is participating in another clinical study Subject is pregnant, nursing, or of
             childbearing potential and is not using adequate contraceptive methods

          -  Subject has renal arteries with diameter(s) &lt; 4 mm in diameter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephen G Worthley, Prof</last_name>
    <email>stephen.worthley@adelaide.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Nimmo</last_name>
      <phone>08 8222 2899</phone>
      <email>joanne.nimmo@health.sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Stephen Worthley, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>Stephen Grant Worthley</investigator_full_name>
    <investigator_title>Helpman Chair of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Renal denervation</keyword>
  <keyword>Renal artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

